Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Technical Presentation (September 2022)
28 slides from Nova Eye Medical's technical presentation, Sep 15, 2022
Slide 1: 2RT Webinar Presentation by Professor Robyn H. Guymer
ASX RELEASE 15 September 2022 For personal use only 2RT® Webinar Presentation by Professor Robyn H. Guymer, MBBS, PhD Today Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is plea
Slide 2: About Nova Eye Medical Limited
ABOUT NOVA EYE MEDICAL LIMITED Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells For personal use only a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies i
Slide 3: 2RT Webinar Presentation by Professor Robyn H. Guymer, MBBS, PhD
2RT® WEBINAR PRESENTATION BY PROFESSOR ROBYN H. GUYMER, MBBS, PHD For personal use only Professor Guymer AM is the Deputy Director, Centre for Eye Research Australia (CERA) and Professor in the Department of Surgery (Ophthalmology), University of Melbourne, and Senior Medical Retinal Specialist, Roy
Slide 4: Presentation of the AlphaRET 2RT laser program in AMD
For personal use only Presentation of the AlphaRET 2RT laser program in AMD. Robyn Guymer 2
Slide 5: Age related macular degeneration (AMD)
Age related macular degeneration (AMD) For personal use only The most common cause of irreversible vison loss in people over 50 in our community 3
Slide 6: The macula
The macula A normal macula For personal use only 4
Slide 7: Age-related macular degeneration end stage without treatment
Age–related macular degeneration For personal use only End stage without treatment 5
Slide 8: Age-related macular degeneration
Age-related macular degeneration For personal use only • Reading • Recognizing faces • Driving 6
Slide 9: For personal use only
For personal use only 7
Slide 10: Stages of AMD: early, late dry and late wet
For personal use only Late Atrophic AMD (DRY) Early Stages of AMD (early and iAMD) Death or neural tissue (“dry”) Late Neovascular AMD (WET) One in seven over 50 years old Bleeding and fluid leakage (“wet”)
Slide 11: Global prevalence of AMD
• The global prevalence of AMD in 2020 was estimated to be 196M For personal use only • With the ageing population, the prevalence of AMD is estimated to grow to 288 million in 2040 • ~15% of the global population over 50 years of age are estimated to have some form of AMD. • The prevalence of • non
Slide 12: AMD increases exponentially with age
AMD increases exponentially with age For personal use only Annual incidence of AMD by 5year age groups per 1000 cases of AMD Rudnicka, A. R. et al. Incidence of late- stage age- related macular degeneration in American whites: systematic review and meta- analysis. Am. J. Ophthalmol. 160, 85–93.e83 (
Slide 13: Stages of AMD
Stages of AMD For personal use only WET DRY 11 Fleckenstein M et al. Nature Reviews Disease Primers Age- related macular degeneration. 2021.7:31
Slide 14: Stages of AMD and treatment
Stages of AMD and treatment For personal use only WET: • The only stage of AMD that has a treatment is the late exudative AMD. • Treatment are expensive, frequent long term, injections into the eye • Huge expense on the health system and burden on clinicians and patients DRY • Soon to have our first
Slide 15: AlphaRET 2RT laser in early AMD
Late Atrophic AMD ( DRY) AlphaRET 2RT laser For personal use only Early Stages of AMD x Death or neural tissue (“dry”) Late Neovascular AMD (WET) One in seven over 50 years old Bleeding and fluid leakage (“wet”)
Slide 16: AlphaRET 2RT laser
AlphaRET 2RT laser For personal use only • There is an urgent need for an effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications. • Could 2RT laser specifically trigger a response that would slow
Slide 17: LEAD randomized clinical trial
Ophthalmology 2019;126:829-838 For personal use only + • 292 participants across 6 sites followed for 3 years, • half received subthreshold nanosecond laser (SNL) wit the 2RT laser every 6 months, half received sham treatment • Results • Overall, progression to late AMD was not significantly slowed
Slide 18: Post hoc analysis of AMD subgroups
Failure plot of progression to late AMD. Post hoc analysis- different AMD subgroups Cumulative proportion of For personal use only ▪ There was strong evidence of a significant treatment late AMD effect modified by the presence, at baseline, of a particular deposit in the retina call RPD. RPD are tho
Slide 19: 2RT laser effect on progression to late AMD
Early Stages of AMD Alpha RET Late Atrophic AMD 2RT laser For personal use only 3/4 x Death or neural tissue (“dry”) Late Neovascular AMD 1/4 x Bleeding and fluid leakage (“wet”)
Slide 20: We need a validation study
For personal use only Early Stages of AMD 2RT laser Late Atrophic AMD x Death or neural tissue (“dry”) Late Neovascular AMD We need a validation study To confirm slowing progression from iAMD Bleeding and fluid leakage (“wet”)
Slide 21: Late-stage AMD GA treatment trials
Late-stage AMD- GA treatment trials For personal use only Current trials aim to slow progression of GA growth, not to stop or reverse it. • They measure growth of GA over time • It would be ideal to start earlier before there is significant cell death • Prevention of progression to GA is critical si
Slide 22: Nascent geographic atrophy within iAMD
Within iAMD there will be a group who are more progressed For personal use only > On OCT these features nascent geographic atrophy (nGA) > Nascent = just coming into existence and beginning to display signs of future potential Wu Z, et al. Ophthalmology. 2014 8;121(12):2415-22. 20
Slide 23: Beginning of cell death seen on OCT scan
The beginning of cell death as seen on OCT scan For personal use only 2RT laser x 250um Nascent GA (nGA) 21
Slide 24: Planned international studies
Planned international studies For personal use only 1. Repeat LEAD (without RPD) to show we can slow progression of iAMD to late AMD. (Cohort B) Cohort B, ~600 patients with a high risk of AMD progression, Follow up for 36 months 2. New subgroup study: slow progression from the earliest signs for ce
Slide 25: What does success look like?
What does success look like? For personal use only • People identified through optometry or a family history with early stages of AMD are referred to an ophthalmologist (~1 in 10 people over 50) • Images are performed to confirm iAMD and exclude those with RPD or those with late stage AMD • 2RT lase
Slide 26: Thank you
For personal use only Thank you 24
Slide 27: Thank you Professor Guymer. Any Questions?
2RT® WEBINAR PRESENTATION BY PROFESSOR ROBYN H. GUYMER, MBBS, PHD For personal use only Thank you Professor Guymer. Any Questions? alpha-ret.com | 25
Slide 28: Estimate of Addressable Market
Estimate of Addressable Market For personal use only Intermediate stage disease - AlphaRET Late stage macular degeneration (Treats underlying 0 causes of AMD.) Intermediate Intermediate Wet Dry AMD AMD (GA) AMD AMD (CNV) 54 million Choroidal Neovascularization Geographic Atrophy 55 million 14 millio
Nova Eye Medical — Technical Presentation (September 2022) on 6ix